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Background: Esophagitis caused by gastroesophageal reflux disease (GERD) results in appreciable morbidity and eco-
nomic burden. No systematic review has addressed the effectiveness of prokinetic drugs in the treatment of GERD 
esophagitis in adults. 
Objective: To determine the utility of prokinetic drugs in improving symptoms and endoscopic lesions in patients with 
GERD esophagitis. 
Methods: We included randomized controlled trials that compared prokinetic drugs with placebo. A systematic search 
included the Cochrane Controlled Trial Register, MEDLINE, CINAHL, LILACS, EMBASE, a manual search of books 
and article references, and contact with pharmaceutical companies. Reviewers assessed methodological quality and ex-
tracted data that were combined using a random effects model. 
Results: Eighteen articles met the eligibility criteria; of these, 13 used prokinetic drugs alone, 4 tested prokinetic drugs 
as additional therapy in patients receiving histamine-2 receptor blockers, and 1 tested them in patients receiving pro-
ton pump inhibitors. Seven studies evaluated clinical improvement only, 5 addressed endoscopic improvement only, 
and 6 reported both outcomes. Four studies failed to provide adequate data for pooling; 3 of the 4 reported results that 
suggested symptomatic benefit with prokinetic agents. Nine studies (379 patients) that provided the required data sug-
gested a higher incidence of clinical improvement with prokinetic drugs versus placebo (relative risk [RR] 1.70, 95% 
confidence interval [CI] 1.37–2.12, heterogeneity p = 0.47, I2 = 0%). Clinical improvement occurred in 53 out of 175 pa-
tients (30%) of the control group; applying the relative risk of 1.70 and associated confidence interval suggests that ab-
solute increases in patients improved might vary from 18% to 41% (number needed to treat approximately 3 to 6). Im-
provement was similar in 4 studies in which the prokinetic agent was added to an antisecretory drug. The funnel plot, 
however, suggests the possibility of publication bias. Eleven studies (887 patients) suggested a higher likelihood of en-
doscopic improvement or healing esophagitis with prokinetic drugs (RR 1.26, 95% CI 1.03–1.53) but with significant 
heterogeneity (heterogeneity p = .05, I2 = 46.2%) that we couldn’t explain with an a priori hypothesis. When we evalu-
ated endoscopic healing as the main outcome we observed a trend toward better results in the treatment group, also 
with inexplicable heterogeneity (RR 1.36, CI 95% 0.97–1.89, I2 = 61%).  
Conclusions: Randomized controlled trials provide moderate-quality evidence that prokinetic drugs improve symp-
toms in patients with reflux esophagitis and low-quality evidence that they have an impact on endoscopic healing. 
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sophagitis  is  a  frequent  complication  of  gas-
troesophageal reflux disease (GERD). The di-
versity of clinical manifestations and the lack 
of standardized diagnostic criteria across studies create 
difficulties in estimating its prevalence.1,2 Pathophysi-
ologic  mechanisms  include  anatomic  and  functional 
changes  of  the  gastroesophageal junction  (hiatal  her-
nia, decrease of the inferior esophageal sphincter tone 
and  esophageal  clearance).3  Definitive  diagnosis  of 
esophagitis requires endoscopy and biopsy.4 
  Chronic  esophagitis  complications  include  bleed-
ing, esophageal stenosis, Barrett metaplasia and ade-
nocarcinoma. The goal of medical treatment is to de-
crease symptoms  and complications  by the suppres-
sion  of  gastric  acid  secretion  and  by  ameliorating 
motor dysfunction. Therapeutic options include pro-
ton pump inhibitors (PPIs), histamine-2 receptor (H2) 
antagonists and prokinetic drugs. 
  Prokinetic  drugs  have  potential  usefulness  as  ad-
junctive treatment of GERD by increasing lower eso-
phageal sphincter pressure, enhancing gastric empty-
ing,  and  improving  peristalsis.  A  clinical  practice 
guideline on GERD esophagitis1 suggested the poten-
tial benefit of promotility agents, either as monother-
apy or used in association with PPI. The authors em-
phasized the need for continued research into the role 
of these agents.  
  Any further research or recommendations regarding 
prokinetic agents should, however, be based on a sys-
tematic  summary  of  evidence  to  date.  Although  sys-
tematic reviews have examined the short-term impact 
of prokinetic agents5 on gastroesophageal reflux symp-
toms in patients without endoscopically proven esoph-
agitis,6 no systematic review has evaluated their effect 
on  endoscopically  proven  esophagitis  in  adults.  We 
therefore  undertook  a  systematic  review  and  meta-
analysis to evaluate the real effectiveness of prokinetic 
drugs in patients with proven GERD esophagitis. 
Methods 
Eligibility criteria. We included all published and 
unpublished  parallel-group  randomized  or  quasi-
randomized  controlled  trials  published  in  Spanish, 
English, French,  German, Italian or Portuguese that 
met the following criteria: 
Patients: adults > 15 years with endoscopic diagnosis 
of reflux esophagitis (with or without histology). 
Intervention:  use  of  oral  prokinetic  agents  (cis-
apride, mosapride, tegaserod, metoclopramide, dom-
peridone, bethanechol, levosulpiride, cinitapride, cle-
bopride) compared with placebo. Studies in which pa-
tients  received  antisecretory  agents  (PPI  or  H2 
antagonists) were included only if both the treatment 
and control groups received these agents according to 
the same protocol. 
Outcomes:  symptomatic  improvement  (heartburn, 
regurgitation, dysphagia, retrosternal pain) or endo-
scopic findings. 
We excluded studies with the following characteristics: 
•  Patients: those with esophageal involvement of a 
systemic  illness  (scleroderma,  dermatomyositis), 
dysphagia  of  neurologic  cause,  previous  gastrec-
tomy or antireflux surgery. 
•  Intervention: use of prokinetics after satisfactory 
treatment with PPI or for symptomatic relapse. 
•  Trial design: trials with scores of ≤ 3 in the Jadad 
scale modified by Schulz criteria (score 0 to 8).7 
Titles and abstracts were independently reviewed by 2 
of the authors (MEM and FAS) to identify potentially 
eligible articles. We obtained full-text versions of po-
tentially eligible articles, which the same 2 reviewers 
evaluated.  In  case  of  disagreement,  1  of  3  other  re-
viewers (MFK, GG and HNC) made the eligibility de-
cision. 
Search  strategy.  We  searched  relevant  articles  in 
the  following  electronic  databases:  LILACS  (1985–
2007),  MEDLINE  (1966–2007),  EMBASE  (1980–
2007),  CINAHL  (1982–2007),  COCHRANE  Con-
trolled  Trial  Register  (Cochrane  Library  2007).  The 
terms used were the names of prokinetic agents (both 
generic  and  proprietary),  combined  with  reflux 
esophagitis and therapeutic categories. We also hand-
searched  abstracts  reported  at  the  7th  United  Euro-
pean  Gastroenterology  Week  (UEGW,  November 
1999), the  11th UEGW (November 2003) and at the 
Digestive Diesase Week and the 104th Annual Meet-
ing  of  the  American  Gastroenterological  Association 
(May  2003)  We  reviewed  the  reference  lists  of  in-
E Research                                                                                       Manzotti et al 
Open Medicine 2007;1(3):e171–80 
cluded articles, other sources such as UptoDate (2007 
version 15.1) and relevant gastroenterology, pharma-
cology and internal medicine textbooks. We also con-
tacted a local expert and 5 pharmaceutical companies 
(Beta,  Roux-Ocefa,  Janssen-Cilag,  Phoenix,  and 
Cetus) to identify unpublished articles. 
Quality. Two of  the authors  (MEM and FAS) inde-
pendently evaluated concealment allocation, blinding 
and  completeness  of  follow-up.  The  reviewers  used 
the Jadad scale modified by Schulz criteria to evaluate 
and classify the quality of the studies.7 
Data  abstraction.  Two  of  the  authors  (MEM  and 
FAS)  independently  abstracted  the  data  in  duplicate. 
Patient characteristics, interventions (drugs used, dose, 
time  of  administration,  co-interventions),  outcome 
measures (symptomatic or endoscopic response, endo-
scopic  healing  and  adverse  events)  were  abstracted, 
and any disagreement was resolved through discussion. 
We made attempts to contact authors regarding con-
firmation or missing data; 2 authors answered our re-
quest. Abstracts provided no eligible studies. 
Quantitative  data  synthesis  and  statistical 
analysis.  We used weighted  kappa scores to assess 
agreement between the reviewers on the selection of 
articles for inclusion. We calculated relative risk (RR) 
and  absolute  risk  reduction  (ARR)  with  95%  confi-
dence intervals (CIs) for symptomatic and endoscopic 
response, and combined the  RR  from each study  by 
means of a meta-analytic technique using a random 
effects  model  as  described  by  DerSimonian  and 
Laird.8 RevMan 4.2 was used to analyze all data.  
  The authors of the trials used different scores to as-
sess improvement (e.g., 0 to 100 symptom scale; cate-
gorical scale from absent to disabling symptoms). We 
used the authors’ own criteria in each trial to classify 
patients as improved or unimproved.  We considered 
outcomes  of patients free of symptoms  and patients 
with  symptomatic  improvement  as  equivalent,  and 
pooled each outcome of interest based on the a priori 
expectation  of  a  similar  magnitude  and  direction  of 
treatment  effect.  We  classified  “some  improvement” 
with complete symptom resolution as a positive out-
come and “no improvement” as a negative outcome. 
  Heterogeneity of the studies was evaluated both by 
the chi-square test with a threshold p value of < 0.05, 
and by the I2 statistic (considering important hetero-
geneity a proportion higher than 30%). For any out-
come that crossed either threshold for heterogeneity, 
we explored sources of heterogeneity according to our 
a  priori  hypothesis,  which  included  drugs  used,  the 
use of additional agents, dosing, duration of treatment 
and methodological quality. Specifically, we compared 
the results of studies grouped by the following factors:  
•  different  drugs  used  (cisapride,  metoclopramide, 
bethanechol, levosulpiride, domperidone, mosaprid)  
•  use of antisecretory agents (yes or no) 
•  dose of prokinetic drugs used per day (< 40 mg v. ≥ 
40 mg of cisapride, < 40 mg v. ≥ 40 mg metoclo-
pramide) 
•  treatment duration (≤ 8 weeks v. > 8 weeks) 
•  methodological qualtity (Jadad score 4 v. ≥ 5).  
We used log-transformed  RR and its standard error 
calculated from 95% CI and Z value to obtain p values 
for testing explanations of heterogeneity.  
  All data were analyzed on an intention-to-treat prin-
ciple. Publication bias was evaluated using funnel plots. 
Results 
We identified 1,119 abstracts (Fig. 1). None of 15 stud-
ies  provided  by  pharmaceutical  companies  fulfilled 
eligibility criteria. Eighteen9-26 randomized controlled 
trials (RCTs) enrolling 1,155 patients (621 in the inter-
vention  and  504  in  the  placebo  group;  Table  1),  all 
identified from electronic  databases, proved eligible. 
Table  2  shows  characteristics  and  methodological 
quality of the eligible trials. Eleven trials were rated 4 
using the Jadad scale modified by Schulz criteria, and 
7 were rated 5 or  more;  11 trials were sponsored  by 
pharmaceutical  industry.  Six  RCTs  failed  to  provide 
sponsorship information, and 1 had no sponsor. 
  Eleven  trials  evaluated  the  effect  of  cisapride.  Of 
these, 1 trial evaluated 80 mg/d dose, 9 trials the 40 
mg/d dose, 2 trials the 30 mg/d dose and only 1 trial 
the 15 mg/d dose. Metoclopramide was evaluated in 3 
studies; 1 evaluated the 30 mg/d dose and the other 2 
the 40 mg/d dose. One study evaluated bethanechol, 1 
study  evaluated  mosapride  and  2  studies  evaluated 
each  of  sulpiride  and  domperidone.  Four  trials  com-
pared the addition of a prokinetic drug versus placebo 
in  patients  already  using  an  H2  receptor  blocker  (3 
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cimetidine and  1 ranitidine). One trial evaluated the 
addition of a prokinetic agent to a PPI. 
  Tables 3 and 4 show primary outcomes and adverse 
reactions. 
Studies that did not provide data for pooling. 
Masci and colleagues17 evaluated the presence and se-
verity  of  reflux  symptoms  (dysphagia,  regurgitation, 
heartburn,  retrosternal  pain,  nausea),  comparing 
levosulpiride,  domperidone  and  placebo.  They  re-
ported  equal  effectiveness  of  both  drugs  in  signifi-
cantly  reducing  regurgitation,  heartburn  and  overall 
dyspeptic  symptoms  (p  <  0.05  compared  with  con-
trol). Endoscopic features failed to reveal significant 
differences between groups. 
  Trabucchi and colleagues26 compared levosulpiride 
with  placebo.  They  reported  improvement  in  symp-
tom  score  in  most  patients  in  the  treatment  group. 
Endoscopic lesions disappeared in 20%, improved in 
47%  and  failed  to  improve  in  33%.  The  authors  did 
not provide data for the placebo arm. 
  Finizia and colleagues11 reported no significant dif-
ference on symptom score according to intensity, fre-
quency and duration in the cisapride group compared 
to placebo. 
  Pehlivanov and colleagues21 found fewer heartburn 
episodes  during  daytime  and  fewer  antacid  tablets 
needed per patient in a week in the cisapride group 
versus the placebo group, with a p value of 0.016 and 
0.062, respectively.  
Clinical  improvement.  Nine  studies  (379  pa-
tients)  evaluated  clinical  improvement.  The  pooled 
estimate  showed  a  significant  improvement  with 
prokinetic  drugs  versus  placebo  (RR  1.70,  95%  CI 
1.37–2.12). Results were consistent across studies (p 
= 0.47, I2 = 0%). The ARR was 30% (95% CI 18%–
41%) (Table 3).   
 
 







                          
 
 
        
















Interobserver agreement kappa score 0.62 
 
 
Figure 1: Selection of studies for systematic review 
 
  
RCTs included in this review = 18 
Potentially relevant RCTs identified and screened for retrieval = 1,119 
1,052 excluded 
Citations retrieved for more detailed evaluation = 67 
Reasons for exclusion 
Duplicate or updated publication (n = 52) 
Not RCT (n = 528) 
Patients, intervention, or outcome do not meet inclusion criteria (n = 451) 
Language (n = 21) 
Reasons for exclusion  
Duplicate or updated publication (n = 13) 
Not RCT (n = 5) 
Patients, intervention, or outcome do not meet inclusion criteria (n = 28) 
Language (n = 3) 
RCTs with data amenable to statistical analysis:  
Symptom improvement (n = 9) 
Endoscopic improvement (n = 11) 
Adverse events (n = 12) 
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 Table 1: General characteristics of randomized controlled trials included in analysis 
Study (country and year)  n  Drug, dose, posology 
Concomitant treatment 






9 (Italy 1988)   63  Cisapride 10 mg × 4   None  12 w 
Collins et al
10 (UK 1987)   18  Cisapride 10 mg × 3  None  4 w 
Finizia et al
11 (Sweden 2002)   30  Cisapride 20 mg × 2  None  2 w 
Galmiche et al
12 (France 1988)   47  Cisapride 10 mg × 4 + cimetidine  Cimetidine  12 w 
Hatlebakk et al
13  (Norway 1999)   107  Cisapride 20 mg × 2  None  8 w 
Lepoutre et al
14 (Belgium 1990)  20  Cisapride 10 mg × 4   None  16 w 
Lieberman et al
15 (US 1986)  25  Metoclopramide 10 mg × 4 + cimetidine  Cimetidine  8 w 
Madan et al
16 (India 2004)  32  Lansoprazole 40 mg × 2 + mosapride 5 mg  x 3    Lansoprazole  8 w 
Masci E et al
17 (Italy 1992)   30*  Levosulpiride 25 mg × 3 / domperidone 10 mg x 3  None  12 w 
McCallum et al
18 (US 1984)   19  Metoclopramide 10 mg × 4   None  4 w 
McKenna et al
19 (UK 1995)   344  Cisapride 20 mg × 2 + ranitidine  Ranitidine  12 w 
Nicolaidis et al
20 (1987
 Greece)  40  Cisapride 10 mg × 3  None  4 w 
Nicolaidis et al
20 (1987 Greece)  40  Cisapride 5 mg × 3  None  4 w 
Pehlivanov et al
21 (2002
 US)  10  Cisapride 10 mg × 4   None  5 d 
Richter et al
22 (1995
 US)  177  Cisapride 10 mg × 4   None  12 w 
Richter et al
22 (1995 US)  177  Cisapride 20 mg × 4   None  12 w 
Robertson
23 (1993 UK)  46  Cisapride 10 mg × 4   None  12 w 
Temple
24 (1983 UK)  73  Metoclopramide 10 mg × 3 + cimetidine  Cimetidine  12 w 
Thanik et al
25 (1980
 US)  44  Bethanechol 25 mg × 4  None  4 w 
Trabucchi et al
26 (1991
 Italy)  30  L-sulpiride 25 mg × 3  None  4 w 
*Number of patients enrolled in each arm was not reported. 
UK = United Kingdom; US = United States; w = weeks; d = days 
 
Endoscopic improvement. Five of 11 studies used 
a validated scale (Savary-Miller [3], Los Angeles [1], 
Hetzel [1]); the other 6 scales used were similar to one 
another.  The  pooled  estimate  of  treatment  effect  on 
endoscopic  healing  or  improvement  from  11  studies 
including 887 patients demonstrated a significant ef-
fect of prokinetic drug versus placebo (RR 1.26, 95% 
CI  1.03–1.53);  the  risk  difference  was  16%  (CI  95% 
3%–29%).  The  results  were,  however,  variable  from 
study to study (test for heterogeneity p = 0.05, I2  = 
46.2%). We therefore explored the possible sources of 
heterogeneity  according  to  our  a  priori  hypothesis. 
The a priori hypotheses failed to explain the variabil-
ity in study results.  
Endoscopic healing. The  pooled  estimate  of treat-
ment effect on endoscopic healing from eight studies 
including  796  patients  demonstrated  a  trend  toward 
better results with prokinetic treatment (RR 1.36, 95% 
CI  0.97–1.89)  with  significant  heterogeneity  between 
groups (test for heterogeneity p = 0.001, I2 = 61.4%). 
Once  again,  our  a priori  hypotheses  failed to  explain 
the variability observed.  
Adverse  events.  Twelve  trials  reported  adverse 
events. They showed a non-significant increase in ad-
verse  reactions  (RR  1.30,  95%  CI  0.93–1.83),  with 
substantial  variability  between  the  studies  (test  for 
heterogeneity  p =  0.08, I2 = 39.4%); the risk differ-
ence was 9% (CI 95% 0%–18%) (Table 4).  
Discussion 
Our  intention  was  to  determine  the  quality  of  evi-
dence and apparent magnitude of impact of prokinetic 
agents on symptoms, endoscopic healing, and adverse 
effects  in  patients  with  gastroesophageal  reflux.  We 
found an increase in the probability of symptom im-
provement of 70% with treatment (RR 1.70, 95%  CI 
1.37–2.12), and an increase of 26% (RR 1.35, 95% CI 
1.03–1.53) in the probability of endoscopic healing or 
improvement,  but  we  did  not  find  a  significant  in-
crease in adverse reactions with treatment (RR 1.30, Research                                                                                       Manzotti et al 
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 Table 2: Quality of randomized controlled trials included in analysisncluded in analysis 
Study  Blinding  Method of blindng   Follow-up 
Jadad scale 






9  No  Patients and investigators*  59%  4  NA 
Collins et al
10  No  Patients, health care providers and investigators*  100%  5  Yes 
Finizia et al
11  No  Patients and investigators*  100%  4  Yes 
Galmiche et al
12  No  Patients and investigators*  100%  4  NA 
Hatlebakk et al
13  Yes  Patients, health care providers and data collectors  100%  7  Yes 
Lepoutre et al
14  No  Patients and investigators*  100%  4  NA 
Lieberman et al
15  No  Patients and investigators*  96%  4  Yes 
Madan et al
16  Yes  Patients, health care providers, follow-up endoscopists 
and investigators 
100%  8  NA 
Masci et al
17  No  Double blind*  NA  4  Yes 
McCallum et al
18  No  Patients and investigators*  95%  5  No 
McKenna et al
19  Probably  Patients, follow-up endoscopists and investigators*  92%  4  Yes 
Nicolaidis et al
20  No  Patients and investigators*  100%  5  NA 
Pehlivanov et al
21  No  Patients and investigators*  100%  4  Yes 
Richter et al
22  No  Patients and investigators*  89%  5  Yes 
Robertson et al
23  No  Double blind*  96%  4  Yes 
Temple et al
24  No  Patients and investigators* (double dummy technique)  96%  4  Yes 
Thanik et al
25  No  Patients and investigators*  100%  5  Yes 
Trabucchi et al
26  No  Double blind*  NA  4  NA 
*Not defined further.  NA = not available. 
 
95% CI 0.93–1.83). The last 2 outcomes showed sub-
stantial variability between the studies.  
  The  GRADE  system  of  rating  quality  of  evidence 
provides  a  structure  for  assessing  the  quality  of  the 
evidence.27 In the GRADE system, randomized trials 
constitute high-quality evidence unless there are im-
portant  limitations.  The  12  trials  that  addressed 
symptomatic improvement were of moderate to high 
quality; their results  were consistent, the confidence 
intervals  reasonably  narrow,  and  the  results  applied 
directly to the relevant population (Table 5). However, 
the trials were small, a number were funded by indus-
try, and the funnel plot (see Appendices) suggests the 
possibility  of  publication  bias  —  a  substantial  risk 
when evidence comes from a number of small trials. 
In  our  judgment,  therefore,  we  have  moderate  evi-
dence of symptomatic benefit with prokinetic agents. 
   With respect to endoscopic improvement, the 10 
relevant randomized trials were of moderate to high 
quality  and  provide  direct  evidence  regarding  the 
impact  of  prokentic  agents.  The  results,  however, 
were not consistent across studies (test for hetero-
geneity p = 0.05, I2 = 46.2%) and our a priori hy-
potheses failed to explain differences in the magni-
tude  of  effect  across  studies.  Moreover,  the  confi-
dence  intervals  around  the  effect  were  wide  (RR 
1.26, 95% CI 1.03–1.53), and the pattern of results 
suggest  the  possibility  of  publication  bias.  We 
therefore  conclude  that  the  results  provide  only 
weak evidence supporting the benefits of prokinetic 
agents on endoscopic healing.  
  With respect to adverse effects, these randomized 
trials were of moderate to high quality and the results 
are directly applicable to the patient population. The 
results are,  however, inconsistent (test for heteroge-
neity p = 0.08, I2 = 39.4%) and the confidence inter-
vals  wide  (RR  1.30,  95%  CI  0.93–1.83).  The  results 
therefore provide weak evidence of toxicity of proki-
netic agents. Furthermore, the studies are extremely 
underpowered to detect rare but serious side effects. 
Case reports of cardiovascular adverse effects remain, 
therefore, an important concern.28–30 Research                                                                                       Manzotti et al 
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 Table 3: Prokinetic drug utility 
Patients improved, n (total) 
Agent and outcome 
No. of studies 
(patients) 
Treatment 
group  Control group 
RR of random effect 
(95% CI)  
Risk difference  
 for random effect  
(95% CI) 
Cisapride < 40 mg/d           
Clinical improvement  2 (58)  29 (37)  9 (21)  1.77 (1.03–3.04)  34% (9–60) 
Cisapride ≥ 40 mg/d               
Endoscopic improvement or healing  3 (244)  98 (151)  46 (93)  1.57 (1.01–2.42)  36% (1–72) 
Clinical improvement  4 (220)  52 (113)  33 (107)  1.49 (1.13–1.96)  16% (6–27) 
Cisapride (any dose)               
Endoscopic improvement or healing   6 (757)  254 (378)  200 (379)  1.43 (1.1–1.85)  26% (10–41) 
Clinical improvement  6 (278)  81 (150)  42 (128)  1.54 (1.21–2.11)  19% (9–29) 
Metoclopramide 30 mg/d               
Endoscopic improvement or healing   1 (73)  8 (33)  18 (40)  0.54 (0.27–1.08)  –21% (–42 to 0) 
Metoclopramide 40 mg/d               
Endoscopic improvement or healing  2 (45)  15 (24)  10 (21)  1.26 (0.5–3.19)  13% (–34 to 60) 
Clinical improvement   1 (22)  9 (13)  2 (9)  3.12 (0.87–11.15)  47% (10–84) 
Metoclopramide (any dose)               
Endoscopic improvement or healing   3 (118)  23 (57)  28 (61)  0.93 (0.45–1.94)  –1% (–36 to 35) 
Clinical improvement   1 (22)  9 (13)  2 (9)  3.12 (0.87–11.15)  47% (10–84) 
Bethanechol 100 mg/d               
Endoscopic improvement or healing  1 (44)  14 (22)  8 (22)  1.75 (0.93–3.31)  27% (–1 to 56) 
Clinical improvement  1 (44)  10 (22)  3 (22)  3.67 (1.18–11.37)  36% (11–62) 
Mosapride 15 mg/d                
Endoscopic improvement or healing  1 (32)  12 (17)  6 (11)  1.29 (0.7–2.41)  16% (–20 to 53) 
Clinical improvement  1 (32)  18 (19)  7 (13)  2.05 (1.13–3.73)  49% (20–77) 
All prokinetics               
Endoscopic improvement or healing   11 (947)  303 (474)  252 (473)  1.26 (1.03–1.53)  16% (3–294) 
Clinical improvement  9 (379)  119 (204)  53 (175)  1.70 (1.37–2.12)  30% (18–41) 




















 Table 4: Adverse effects 
Adverse effects  Intervention 
RR of random 
effect (95% CI) 
Risk difference of  
random effect (95% CI) 
No. of 
 studies 
General   Any prokinetic and dose  1.30 (0.93–1.83)  9%   (0–18)  12 
Gastrointestinal (any)  Any prokinetic and dose  1.09 (0.66–1.79)  0%   (–5 to 5)  8 
Neurological (any)  Any prokinetic and dose  1.03 (0.58–1.84)  0.04%   (–0.04 to 0.12)  9 
Gastrointestinal (any)  Cisapride (any dose)  1.05 (0.64–1.74)  0%   (–0.07 to  0.06)  7 
Neurological (any)  Cisapride (any dose)  0.61 (0.32–1.15)  –0.02%  (–0.09 to 0.05)  6 
Headache  Cisapride > 40 mg/d  0.65 (0.33–1.28)  0%   (–0.08 to 0.08)  4 
Diarrhea  Cisapride > 40 mg/d  0.99 (0.47–2.09)  –0.01%   (–0.09 to 0.07)  3 
Neurological (any)  Metoclopramide (any dose)  2.41 (1.25–4.64)  34%   (–16 to 83)  2 
RR = relative risk; CI = confidence interval; d = day Research                                                                                       Manzotti et al 











Strengths of our systematic review include explicit, de-
tailed eligibility criteria; a comprehensive search; restric-
tion to RCTs of moderate or high methodological qual-
ity; high  levels of agreement on issues requiring judg-
ment; and our use of the systematic GRADE approach to 
rate the quality of the evidence. Limitations pertain to 
the number of patients studied and the methodological 
concerns  that  we  have  highlighted  (in  particular,  the 
possibility  of  publication  bias).  With  respect  to  rele-
vance, although cisapride is no longer available in most 
markets, an alternative agent, mosapride, may take its 
place. The one trial of mosapride in this review is nota-
ble both for its high methodological quality and the fact 
that  it  detected  a  benefit  of  mosapride  in  patients  al-
ready receiving a PPI.  
  Although the enthusiasm for PPIs in the treatment 
of reflux esophagitis is appropriate, we do not believe 
it warrants the neglect of other agents. The previous 
lack  of systematic review  and meta-analysis, as pre-
sented here reflects, in our view, a certain neglect. 
  In summary, although patients with reflux esoph-
agitis  are  likely  to  benefit  symptomatically  from  the 
use  of  prokinetic  agents,  some  uncertainty  remains. 
The  magnitude  of  side  effects  and  toxicity  is  uncer-
tain. Clinicians must also consider the higher-quality 
evidence available for other agents (particularly PPIs, 
which  are  superior  to  prokinetic  agents)  in  making 
their therapeutic decisions. 
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    Appendix 1: Forest plot — all prokinetic agents, clinical improvement  











   Appendix 3: Funnel plots — all prokinetic agents, clinical improvement (left),   
 endoscopic healing or improvement (right) 